You are here

FDA Approves Cladribine Injection, Treatment for Hairy Cell Leukemia

SCHAUMBURG, Ill., April 27 /PRNewswire-FirstCall/ -- American Pharmaceutical Partners, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Cladribine Injection. Cladribine is indicated for the treatment of active Hairy Cell Leukemia, and is the generic equivalent of Ortho Biotech's Leustatin® Injection. APP expects to commence marketing cladribine in the third quarter of this year.

"Sales of cladribine were approximately $9 million in 2003," said Patrick Soon-Shiong, M.D., chairman, president and chief executive officer of American Pharmaceutical Partners. "Cladribine adds to our broad oncology product offering and brings to three the number of ANDA approvals APP has received thus far in 2004."

Source: American Pharmaceutical Partners, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs